How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Haemorrhagic Stroke Drugs Market
- By Drug Class: Antihypertensives, Hemostatic Agents, Calcium Channel Blockers, Antifibrinolytics, Neuroprotective Agents
- By Route of Administration: Oral, Intravenous, Intramuscular, Subcutaneous
- By Mechanism of Action: Vasospasm Inhibitors, Coagulation Modifiers, Blood Pressure Regulators, Neuroprotective Agents
- By Patient Type: Acute Haemorrhagic Stroke Patients, Post-Surgical Patients, Chronic Haemorrhagic Stroke Patients
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Antihypertensives leads By Drug Class at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 272 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.163 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.171 →
Full report · locked preview
Everything inside the Haemorrhagic Stroke Drugs Market report
A complete, evidence-based study - 11 chapters and 114 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Drug Class 5
Route of Administration 4
Mechanism of Action 4
Patient Type 3
Companies profiled
Bayer AG
Pfizer Inc.
Novartis AG
Bristol-Myers Squibb Company
AbbVie Inc.
Johnson & Johnson
Amgen Inc.
Sanofi S.A.
Takeda Pharmaceutical Company Limited
AstraZeneca plc
Eli Lilly and Company
Merck & Co. Inc.
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Bayer AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Pfizer Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Bristol-Myers Squibb Company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →AbbVie Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Johnson & Johnson
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Amgen Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Sanofi S.A.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Takeda Pharmaceutical Company Limited
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →AstraZeneca plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Eli Lilly and Company
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Merck & Co. Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Roche Holding AG
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Boehringer Ingelheim GmbH
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Mitsubishi Tanabe Pharma Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$1,985M by 2033 · 10.3% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Antihypertensives53.8
- Hemostatic Agents12.7
- Calcium Channel Blockers9.5
- Antifibrinolytics8.2
- Neuroprotective Agents15.8
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$299.8M → $615.4M · 9.4%
Europe$209.0M → $418.7M · 9.1%
Asia Pacific$190.8M → $448.2M · 11.3%
Latin America$118.1M → $246.6M · 9.6%
Middle East and Africa$90.9M → $203.5M · 10.6%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.212026
10.222027
10.252028
10.262029
10.252030
10.282031
10.282032
10.292033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Bayer AG20.7
- Pfizer Inc.14.9
- Novartis AG8.8
- Bristol-Myers Squibb Company5.8
- AbbVie Inc.12.7
- Johnson & Johnson9.0
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Drug Class19.2%
Route of Administration11.1%
Mechanism of Action34.9%
Patient Type34.8%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.8
- Europe21.7
- Asia Pacific23.2
- Latin America12.8
- Middle East and Africa10.5
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Bayer AG | 83 | 86 | 94 | 96 | 80 | 82 | 87 |
| Pfizer Inc. | 86 | 77 | 79 | 93 | 86 | 72 | 82 |
| Novartis AG | 72 | 82 | 86 | 70 | 84 | 71 | 78 |
| Bristol-Myers Squibb Company | 77 | 59 | 81 | 72 | 71 | 75 | 73 |
| AbbVie Inc. | 54 | 61 | 56 | 74 | 64 | 56 | 61 |
| Johnson & Johnson | 61 | 58 | 47 | 71 | 52 | 55 | 57 |
| Amgen Inc. | 43 | 64 | 50 | 42 | 52 | 43 | 49 |
| Sanofi S.A. | 40 | 51 | 55 | 40 | 39 | 47 | 45 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Bayer AG
- Pfizer Inc.
- Novartis AG
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Bayer AG | ✓ | ✓ | ✓ | ✓ | ✓ | ◐ |
| Pfizer Inc. | ✓ | ✓ | ◐ | ◐ | ✓ | ◐ |
| Novartis AG | ✓ | ✓ | ◐ | ◐ | ✓ | ◐ |
| Bristol-Myers Squibb Company | ✓ | ◐ | ◐ | ◐ | ◐ | ✓ |
| AbbVie Inc. | − | ✓ | − | ◐ | ◐ | ◐ |
| Johnson & Johnson | ◐ | ◐ | − | ✓ | ◐ | − |
| Amgen Inc. | − | ◐ | ◐ | ◐ | − | − |
| Sanofi S.A. | − | − | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Bayer AG87
2Pfizer Inc.82
3Novartis AG78
4Bristol-Myers Squibb Company73
5AbbVie Inc.61
6Johnson & Johnson57
7Amgen Inc.49
8Sanofi S.A.45
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Bayer AGPfizer Inc.Novartis AG
Challenger1
Strong scale, closing on the leaders.
Bristol-Myers Squibb Company
Contender2
Focused players with pockets of strength.
AbbVie Inc.Johnson & Johnson
Niche2
Specialists in a single segment or region.
Amgen Inc.Sanofi S.A.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Drug Class in North America, then scale across Haemorrhagic Stroke Drugs Market — a $374M beachhead inside a $6.62B market.
Beachhead (SOM)$374Mobtainable near-term
Serviceable (SAM)$2.36Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Antihypertensives
Best fit — highest urgency & budget in Drug Class.
Economic buyer79 fit
Hemostatic Agents
Strong fit — clear ROI and a fast path to value.
End user69 fit
Calcium Channel Blockers
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Drug Class in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Route of Administration & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Mechanism of Action
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales47%
Partner / channel27%
Digital / self-serve19%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Drug Class leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Haemorrhagic Stroke Drugs Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified43%
Sales qualified21%
Evaluation15%
Closed-won7%
$11.4KCAC
$41KLTV
3.6:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Haemorrhagic Stroke Drugs Market is a high-growth opportunity — $1.41B by 2033, compounding at 11.3%.
TAM · 2025$599Mtoday
TAM · 2033$1.41Bforecast
CAGR11.3%2027–2033
Cumulative$8.57Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.41BTotal addressable market
SAM$561MServiceable available market
SOM$92MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →11.3% CAGR
Demand compounds through 2033, outpacing GDP across Drug Class.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Drug Class moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.41BLarge & growingTAM by 2033 at 11.3% CAGR
$561MServiceable nowreachable with today’s model
$92MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.10BBear7.3% CAGR
$1.41BBase11.3% CAGR
$1.80BBull14.9% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Route of Administration optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Haemorrhagic Stroke Drugs Market — a $3.95B market by 2033. Plan: grow share from 8.0% to 17.1%.
Market size · 2033$3.95Btotal addressable
Market CAGR8.7%2027–2033
Target share17.1%from 8.0% today
Revenue ambition$676Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.0% | 17.1% | At risk |
| Revenue | $297M | $676M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 32.1% | 43.0% | Ahead |
| Customer retention | 85.8% | 94.8% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Drug Class
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Route of Administration capability
A defensible second engine — invest in Route of Administration to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Drug Class share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Route of Administration
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $90M capacity & capability investment
- Greenlight bolt-on M&A in Route of Administration
- Authorise North America expansion plan
- Fund R&D program for Drug Class leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossAt risk
- Input-cost & supply riskBehind
- Regulatory / policy changeAt risk
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Haemorrhagic Stroke Drugs Market conversation — a $7.82B market you can size, segment and defend in minutes.
Market size · 2033$7.82Btotal opportunity
Growth9.0%CAGR to 2033
Addressable buyers904+accounts in scope
Typical ROI4.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Drug Class
Goal Grow share in Drug Class
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.5×return on cost, year one
< 3 mopayback period
$93K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Bayer AGPfizer Inc.Novartis AGBristol-Myers Squibb CompanyAbbVie Inc.Johnson & JohnsonAmgen Inc.Sanofi S.A.+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Haemorrhagic Stroke Drugs Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Haemorrhagic Stroke Drugs Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Glycerol Phenylbutyrate Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportGlycogen Metabolism and Glycogen Storage Disease Treatment Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportGastric Motility Disorder Drug Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportAI in Medical Imaging and Diagnostics Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportGastrointestinal (GI) Stent Market
Market size, share, segmentation and regional forecast.
$777M market · 2025 base year
View reportAI in Medical Hygiene Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportFocal Adhesion Kinase Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportEpendymoma Drug Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportEnzyme Inhibitor Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportEdaravone Injection Market
Edaravone Injection Market is valued at USD 520 Million in 2025 and is expected to reach USD 82…
$520M market · 2025 base year
View reportCholesterol Medicines Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportAI in Hospital Management Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.